PharmaTher Enters into Research
Collaboration Agreement with Revive Therapeutics for Development of
Psilocybin Microneedle Patch
-
Focusing on
partnership model for MicroDose-MN™ and MacroDose-MN™ patches to
deliver psychedelics.
-
Creating value
and intellectual property protection for psychedelic
programs.
-
Providing
pathways for partners to enter FDA Phase 1 and 2 clinical studies
in 2022 with psychedelics.
TORONTO, November 3, 2021 -- InvestorsHub NewsWire
-- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher")
(OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech
company, is pleased to announce it
has entered into a research collaboration agreement with
Revive Therapeutics Ltd. ("Revive") (OTCQB: RVVTF) (CSE: RVV)
(FRANKFURT:31R), a specialty life sciences company focused on the
research and development of therapeutics for medical needs and rare
disorders, to evaluate the delivery
of psilocybin with PharmaTher's proprietary microneedle ("MN")
patch technology for neuropsychiatric disorders.
PharmaTher is
currently conducting IND-enabling research studies with
MicoDose-MN™, a patent-pending
biocompatible and biodegradable gelatin methacryloyl microneedle
patch, to deliver psilocybin to support an IND application with the
FDA for clinical studies in 2022.
Research
results with MicroDose-MN™ for psilocybin will be
made available in November 2021.
The Company
is also conducting research studies with its
MicoDose-MN™
and MacroDose-MN™
patch as a next generation
delivery system for psychedelics with ketamine,
3,4-methylenedioxy-methamphetamine ("MDMA"), lysergic acid
diethylamide ("LSD"), and N, N-dimethyltryptamine
("DMT").
Also, the
Company has decided to expand research to include ibogaine and
mescaline.
Partnership
opportunities currently exist with MDMA, LSD, DMT, ibogaine and
mescaline for specialty pharmaceutical companies seeking a
differentiated and validated delivery system for psychedelics,
desired pharmacokinetic profiles, intellectual property
protection, cGMP
microneedle patches for IND-enabling and clinical studies,
and a clear
clinical pathway towards FDA Phase 1 and 2 clinical studies in
2022.
The Company's
MicroDose-MN™ and MacroDose-MN™ patches have the potential to
efficiently penetrate the stratum corneum layer (outer layer of the
skin), enable flexible drug load capacity and combinations, and
control-release delivery, which may overcome the potential
drawbacks of oral administration, subcutaneous injections, topical
and nasal delivery systems. In addition to the
potential of maintaining constant plasma levels for more than 24
hours, the MN patches aim to empower patients to dose their
medication remotely, safely and conveniently rather than under
supervision by a healthcare provider at a certified medical office.
To achieve this, the Company will incorporate anti-tampering and
anti-abuse features that would parallel the approach used for the
tamper-resistant transdermal fentanyl patch.
"We are pleased to
collaborate with Revive in achieving their product portfolio
objectives with psilocybin.
Our microneedle patch
technologies aim to become a next generation delivery system for
psychedelics for various indications and healthcare
environments.
Although our focus remains
on building our ketamine-based product pipeline, we will continue
to partner with specialty pharmaceutical companies seeking a
delivery solution for psychedelics and proprietary drugs to unlock
significant value and return on investment for PharmaTher," said
Fabio Chianelli, CEO of PharmaTher.
Michael Frank, CEO of the Company, commented, "Our focus is
developing and commercializing a specialty psilocybin-based product
portfolio, and the research collaboration with PharmaTher
complements our psilocybin product offerings as potential
treatments for mental illness, substance abuse and neurological
disorders.
We believe there is no one-fits-all product profile solution
with psilocybin. For psilocybin to be a next-generation
therapeutic, different use and delivery forms will be required to
achieve the intended target indications. As such, we aim to become a
leader in psilocybin-based solutions for unmet medical needs by
collaborating with companies that have intellectual property and
experience in their delivery technologies, such as
PharamTher."
About Revive Therapeutics
Ltd.
Revive is a life sciences company focused on the research and
development of therapeutics for infectious diseases and rare
disorders, and it is prioritizing drug development efforts to take
advantage of several regulatory incentives awarded by the FDA such
as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric
Disease designations. Currently, the Company is exploring the use
of Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
acquisition of Psilocin Pharma Corp., Revive is advancing the
development of Psilocybin-based therapeutics in various diseases
and disorders. Revive's cannabinoid pharmaceutical portfolio
focuses on rare inflammatory diseases and the company was granted
FDA orphan drug status designation for the use of Cannabidiol (CBD)
to treat autoimmune hepatitis (liver disease) and to treat ischemia
and reperfusion injury from organ transplantation. For more
information, visit www.ReviveThera.com.
About PharmaTher Holdings
Ltd.
PharmaTher Holdings Ltd.
(OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech
company focused on the research, development and commercialization
of novel uses, formulations and delivery methods of psychedelics,
such as ketamine, to treat mental health, neurological and pain
disorders. PharmaTher is currently advancing an FDA
approved phase 2 clinical study with ketamine to treat Parkinson's
disease and is developing a novel microneedle patch for the
intradermal delivery of psychedelics and infectious disease
treatments.
Learn more
at:
PharmaTher.com and follow us on
Twitter and
LinkedIn.
For more information about PharmaTher, please
contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
Neither
the Canadian Securities Exchange nor its Regulation Services
Provider have reviewed or accept responsibility for the adequacy or
accuracy of this release.
Cautionary
Statement
This
press release contains 'forward-looking information' within the
meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated", "potential", "aim" and similar
expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on PharmaTher Holdings Ltd. (the
"Company") current belief or assumptions as to the outcome and
timing of such future events. Forward-looking information is based
on reasonable assumptions that have been made by the Company at the
date of the information and is subject to known and unknown risks,
uncertainties, and other factors that may cause actual results or
events to differ materially from those anticipated in the
forward-looking information. Given these risks, uncertainties and
assumptions, you should not unduly rely on these forward-looking
statements. The forward-looking information contained in this press
release is made as of the date hereof, and Company is not obligated
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
required by applicable securities laws. The foregoing statements
expressly qualify any forward-looking information contained herein.
Factors that could cause actual results to differ materially from
those anticipated in these forward-looking statements are described
under the caption "Risk Factors" in Company's management's
discussion and analysis for the period of August 31, 2021
("MD&A"), dated October 27, 2021, which
is available on the Company's profile at
www.sedar.com.
This news
release does not constitute an offer to sell or the solicitation of
an offer to buy, and shall not constitute an offer, solicitation or
sale in any state, province, territory or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state, province, territory or jurisdiction.
